Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSL Bullish on Immunoglobulins, Bearish On Plasma Pricing

This article was originally published in PharmAsia News

Executive Summary

TOKYO - CSL closed its 2010 fiscal year with a mixed bag of results. From gains in its plasma portfolio to disappointments in Gardasil and influenza vaccines, the Melbourne, Australia-based company's 2011 outlook is a combination of caveats and prospects
Advertisement

Related Content

Abbott, Baxter, Bristol-Myers Squibb: Emerging Markets Earnings Roundup (Part 1 of 3)
Abbott, Baxter, Bristol-Myers Squibb: Emerging Markets Earnings Roundup (Part 1 of 3)
U.S. FDA Issues Untitled Letter To Australia's CSL Biotherapies For GMP Deviations For Flu Vaccine
Advertisement
UsernamePublicRestriction

Register

SC075678

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel